Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: Ford Investor Services, Inc.
$12.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Intercept Pharmaceuticals Inc Announces Proposed Public Offering of Common Stock


Monday, 17 Jun 2013 06:00am EDT 

Intercept Pharmaceuticals Inc announced that it has commenced an underwritten public offering of 1,730,000 shares of its common stock. All of the shares in the offering are to be sold by Intercept. BofA Merrill Lynch and Citigroup are acting as joint book-running managers, BMO Capital Markets is acting as lead manager and Needham & Company, Wedbush PacGrow Life Sciences and Janney Montgomery Scott are acting as co-managers for the proposed offering. Intercept intends to grant the underwriters a 30-day option to purchase up to 259,500 additional shares of common stock. 

Company Quote

224.45
7.81 +3.61%
17 Oct 2014